Company’s 36-month beta value is 1.57.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CTXR is 168.40M, and currently, short sellers hold a 7.00% ratio of that floaft. The average trading volume of CTXR on November 22, 2024 was 1.61M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CTXR) stock’s latest price update
The stock price of Citius Pharmaceuticals Inc (NASDAQ: CTXR) has dropped by -19.32 compared to previous close of 0.17. Despite this, the company has seen a fall of -33.40% in its stock price over the last five trading days. prnewswire.com reported 2024-11-22 that CRANFORD, N.J., Nov. 22, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) (Nasdaq: CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 (“Reverse Stock Split”).
CTXR’s Market Performance
Citius Pharmaceuticals Inc (CTXR) has experienced a -33.40% fall in stock performance for the past week, with a -61.50% drop in the past month, and a -80.41% drop in the past quarter. The volatility ratio for the week is 34.50%, and the volatility levels for the past 30 days are at 19.14% for CTXR. The simple moving average for the past 20 days is -58.80% for CTXR’s stock, with a -79.18% simple moving average for the past 200 days.
Analysts’ Opinion of CTXR
Many brokerage firms have already submitted their reports for CTXR stocks, with Maxim Group repeating the rating for CTXR by listing it as a “Buy.” The predicted price for CTXR in the upcoming period, according to Maxim Group is $4 based on the research report published on November 30, 2021 of the previous year 2021.
CTXR Trading at -66.31% from the 50-Day Moving Average
After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.55% of loss for the given period.
Volatility was left at 19.14%, however, over the last 30 days, the volatility rate increased by 34.50%, as shares sank -62.39% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -73.67% lower at present.
During the last 5 trading sessions, CTXR fell by -31.55%, which changed the moving average for the period of 200-days by -77.62% in comparison to the 20-day moving average, which settled at $0.3235. In addition, Citius Pharmaceuticals Inc saw -82.39% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CTXR
The total capital return value is set at -0.44. Equity return is now at value -41.76, with -36.91 for asset returns.
Based on Citius Pharmaceuticals Inc (CTXR), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -123.48. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -10.01.
Currently, EBITDA for the company is -36.73 million with net debt to EBITDA at 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.75.
Conclusion
In a nutshell, Citius Pharmaceuticals Inc (CTXR) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
